Can BDNF and IL-2 be indicators for the diagnosis in schizophrenic patients with depressive symptoms?
Loading...
Files
Date
2014
Journal Title
Journal ISSN
Volume Title
Publisher
Cambridge Univ Press
Access Rights
info:eu-repo/semantics/closedAccess
Abstract
Objective: The aim of the current study is to determine whether serum levels of brain-derived neurotrophic factor (BDNF) and interleukin-2 (IL-2) can be biological indicators for the diagnosis of schizophrenia in patients with depressive symptoms. Method: Forty-seven patients (11 patients diagnosed with schizophrenia, 16 patients diagnosed with schizophrenia and comorbid depression and 20 patients diagnosed with major depressive disorder) and 20 healthy subjects were enrolled. The Positive and Negative Symptoms Scale, the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale were used for assessment. The serum BDNF and IL-2 levels of all the subjects were studied. Results: Decreased levels of serum BDNF and increased levels of serum IL-2 were found in the patients diagnosed with either schizophrenia, schizophrenia with depression, or major depressive disorder (p = 0.049, p = 0.010; p = 0.001 and p = 0.044; p = 0.027, p = 0.003; respectively) compared with control group. There were no significant differences between the patient groups in their serum BDNF and IL-2 levels. Conclusions: The present study suggests that neurotrophic factors and immune system changes are involved in the pathogenesis of schizophrenia with or without depressive symptomatology. However, the data do not clarify whether depressive symptoms in schizophrenia occur as a dimension of schizophrenia or as symptoms of major depression that is comorbid with schizophrenia.
Description
WOS: 000344995200005
PubMed: 25241757
PubMed: 25241757
Keywords
comorbidity, depression, psychoneuroimmunology, schizophrenia
Journal or Series
Acta Neuropsychiatrica
WoS Q Value
Q4
Scopus Q Value
Q2
Volume
26
Issue
5
